Helping the World Breathe Easier

UBC PHARM SCI GRAD APPLIES HIS EXPERTISE TO IMPROVING ADVANCED INHALED THERAPIES FOR PATIENTS AROUND THE WORLD

You just never know where a graduate degree in pharm sci will take you. Since graduating from UBC with MSc and PhD degrees in pharmaceutical sciences, Dr. Sarvajna Dwivedi has been involved in the development of numerous widely recognized inhaled products involving over 40 molecules in various therapeutic classes and dosage forms, shepherding the process at all stages from discovery to commercialization.

With his outstanding UBC education serving as a solid foundation in his early years, Dr. Dwivedi further grew and developed his knowledge and expertise in pharmaceutical science in partnership with companies such as Glaxo, Dura, Alkermes, and Nektar. At Nektar, Dr. Dwivedi was the director of product development, responsible for new product identification, design, planning and development efforts. At Alkermes, he worked as the director of delivery systems, steering the engineering and development of inhalers for multiple products. At Dura, Dr. Dwivedi led and managed formulation design and development efforts for various Spiros programs. And at Glaxo, Dr. Dwivedi was involved in the development, manufacturing and approval of Flovent® Diskhaler, Serevent® Diskus, Advair® Diskus, Relenza® Diskhaler and Ventolin® Evohaler.

In 2006, Dr. Dwivedi co-founded Pearl Therapeutics with a mission to develop differentiated therapeutics for the prevalent and ever-increasing respiratory disease conditions we see worldwide, including chronic obstructive pulmonary disease (COPD).

Pearl Therapeutics was acquired by AstraZeneca in 2013. Dr. Dwivedi is currently guiding the company through phase three clinical trials as chief scientific officer.